Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model

Eye (Basingstoke)

Volumn 29, Issue 4, 2015, Pages 561-568

  Park, S J ^a   Oh, J ^b   Kim, Y K ^a   Park, J H ^a   Park, J Y ^a   Hong, H K ^a   Park, K H ^a   Lee, J E ^c   Kim, H M ^c   Chung, J Y ^b   Woo, S J ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; CHOROID; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; ENUCLEATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; RABBIT MODEL; TIME TO MAXIMUM PLASMA CONCENTRATION; VITREOUS BODY; ANIMAL; HALF LIFE TIME; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; RABBIT; RETINA;

ANGIOGENESIS INHIBITORS; ANIMALS; AQUEOUS HUMOR; AREA UNDER CURVE; CHOROID; HALF-LIFE; INTRAVITREAL INJECTIONS; MODELS, ANIMAL; RABBITS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINA; VITREOUS BODY;

EID: 84927922537     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2014.329     Document Type: Article

References (26)

1. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. R anibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
2. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
3. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC et al. Ranibizumab fo r macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1102-1112; e1101.
4. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L et al. Ranibizumab for diabetic macular edema: results from phase iii randomized trials: RISE and RIDE. Ophthalmology 2012; 119(4): 789-801.
5. Martin DF, Maguire M G, Fine SL, Ying GS, Jaffe GJ, Grunwald JE et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119: 1388-1398.
6. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99: 11393-11398.
7. Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012; 119: 1658-16 65.
8. Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS Study. Ophthalmology 2014; 121(7): 1414-1420.
9. Korobelnik JF, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U et al. Intravitreal aflibercept injection for macular edema resulting fro m central retinal vein occlusion: one-year results of the phase GALILEO Study. Ophthalmology 2014; 121: 202-208.
10. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninetysix-week results of the VIEW studies . Ophthalmology 2014; 121: 193-201.
11. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 2008; 92: 667-668.
12. Christoforidis JB, Williams MM, Kothandaraman S, Kumar K, Epitropoulos FJ, Knopp MV. Pharmacokinetic properties of intravitreal I-124-Aflibercept in a rabbit model using PET/CT. Curr Eye Res 2012; 37: 1171-1174.
13. Ahn J, Kim H, Woo SJ, Park JH, Park S, Hwang DJ et al. Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes. J Ocul Pharmacol Ther 2013; 29(7): 612-6 18.
14. Ahn SJ, Ahn J, Park S, Kim H, Hwang DJ, Park JH et al. Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes. Invest Ophthalmol Vis Sci 2014; 55: 567-573.
15. Jung K, Lee D, Lim HS, Lee SI, Kim YJ, Lee GM et al. Double anti-Angiogenic and anti-inflammatory protein Valpha targeting VEGF-A and TNF-Alpha in retinopathy and psoriasis. J Biol Chem 2011; 286: 14410-14418.
16. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114: 2179-2182.
17. Nomoto H, Shiraga F, Kuno N, Kimura E, Fujii S, Shinomiya K et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Inve st Ophthalmol Vis Sci 2009; 50: 4807-4813.
18. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005; 46: 726-733.
19. Gaudreault J,Fei D,Beyer JC,Ryan A,Rangell L,Shiu V,et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antib ody fragment directed against VEGF-A, following intravitreal administration in rabbits Retina 2007 27, 1260-1266.
20. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114: 855-859.
21. Sinapis CI, Routsias JG, Sinapis AI, Sinapis DI, Agrogiannis GD, Pantopoulou A et al. Pharmacokinetics of intra vitreal bevacizumab (Avastin(R)) in rabbits. Clin Ophthalmol 2011; 5: 697-704.
22. Kim H, Csaky KG, Chan CC, Bungay PM, Lutz RJ, Dedrick RL et al. The pharmacokinetics of rituximab fo llowing an intravitreal injection. Exp Eye Res 2006; 82: 760-766.
23. Zhang A, Singh SK, Shirts MR, Kumar S, Fernandez EJ. Distinct aggregation mechanisms of monoclonal antibody under thermal and freeze-thaw stresses revealed by hydrogen exchange. Pharm Res 2012; 29: 236-250.
24. Kim H, Robinson SB, Csaky KG. FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis 2009; 15: 2803-2812.
25. Murinello S, Mullins RF , Lotery AJ, Perry VH, Teeling JL. Fcgamma receptor upregulation is associated with immune complex inflammation in the mouse retina and early age-related macular degeneration. Invest Ophthalmol Vis Sci 2014; 55: 247-258.
26. Powner MB, McKenzie JA, Christianson GJ, Roopenian DC, Fruttiger M. Expression of neonatal Fc receptor in the eye. Invest Ophthalmol Vis Sci 2014; 55(3): 1607-1615.